BioNeutra Global Corp. said its third-quarter normalized net income amounted to C$309,420, compared with a loss of C$39,700 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin rose to 3.8% from negative 1.6% in the year-earlier period.

Total revenue climbed on an annual basis to C$8.1 million from C$2.5 million, and total operating expenses climbed on an annual basis to C$7.5 million from C$2.8 million.

Reported net income came to C$18,580, or 0 cents per share, compared to a loss of C$63,520, or a loss of 0 cents per share, in the prior-year period.